Gyre Therapeutics (NASDAQ:GYRE) Trading Down 8.2% – Should You Sell?

Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) were down 8.2% on Wednesday . The company traded as low as $7.12 and last traded at $7.0250. Approximately 68,374 shares changed hands during trading, a decline of 27% from the average daily volume of 93,144 shares. The stock had previously closed at $7.65.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Wall Street Zen lowered shares of Gyre Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. Zacks Research downgraded shares of Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Gyre Therapeutics in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $17.00.

Gyre Therapeutics Trading Down 3.0%

The firm has a 50 day moving average of $7.95 and a 200-day moving average of $7.76. The company has a market cap of $659.33 million, a P/E ratio of 680.68 and a beta of 1.97.

Gyre Therapeutics (NASDAQ:GYRE) last announced its quarterly earnings data on Thursday, March 12th. The company reported $0.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.04). Gyre Therapeutics had a net margin of 4.31% and a return on equity of 10.85%. The company had revenue of $37.20 million for the quarter, compared to analysts’ expectations of $36.30 million.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. State of Alaska Department of Revenue purchased a new position in shares of Gyre Therapeutics during the third quarter valued at about $38,000. Bank of America Corp DE lifted its position in shares of Gyre Therapeutics by 28.8% in the second quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock worth $46,000 after buying an additional 1,402 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Gyre Therapeutics by 84.6% during the second quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock valued at $47,000 after buying an additional 2,961 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Gyre Therapeutics by 77.8% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock valued at $54,000 after buying an additional 3,244 shares during the last quarter. Finally, Dimensional Fund Advisors LP purchased a new position in Gyre Therapeutics during the 4th quarter valued at approximately $77,000. Institutional investors own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.